thalidomide has been researched along with Ischemic Attack, Transient in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "She developed transient ischemic attack after the introduction of lenalidomide plus dexamethasone (Rd) therapy despite no vascular risk factors." | 1.48 | Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. ( Hashida, H; Hatano, K; Irie, K; Matsumoto, H; Mitsutake, A; Tsukada, N, 2018) |
| "Patients with multiple myeloma (MM) are at increased risk of arterial thrombosis." | 1.43 | Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. ( Hinduja, A; Limaye, K; Papanikolaou, X; Ravilla, R; Sasapu, A; Torbey, M; Waheed, S; Wei, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mitsutake, A | 1 |
| Matsumoto, H | 1 |
| Hatano, K | 1 |
| Irie, K | 1 |
| Tsukada, N | 1 |
| Hashida, H | 1 |
| Hauser, P | 1 |
| Vancsó, I | 1 |
| Pócza, T | 1 |
| Schuler, D | 1 |
| Garami, M | 1 |
| Akkoyun, M | 1 |
| Ardıç, I | 1 |
| Balakan, O | 1 |
| Deniz, MS | 1 |
| Acar, G | 1 |
| Hinduja, A | 1 |
| Limaye, K | 1 |
| Ravilla, R | 1 |
| Sasapu, A | 1 |
| Papanikolaou, X | 1 |
| Wei, L | 1 |
| Torbey, M | 1 |
| Waheed, S | 1 |
4 other studies available for thalidomide and Ischemic Attack, Transient
| Article | Year |
|---|---|
Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.
Topics: Adult; Brain; Brain Infarction; Dexamethasone; Female; Humans; Immunologic Factors; Ischemic Attack, | 2018 |
[Antiangiogenic treatment of pediatric CNS tumors in Hungary with the Kieran schedule].
Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemothera | 2013 |
Case images: Isolated thrombus-like mass in a patient with multiple myeloma.
Topics: Angiogenesis Inhibitors; Aorta; Diagnosis, Differential; Humans; Ischemic Attack, Transient; Male; M | 2014 |
Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study.
Topics: Acute Kidney Injury; Antineoplastic Agents; Case-Control Studies; Cerebral Hemorrhage; Hospital Mort | 2016 |